Santhera Pharmaceuticals Holding AG (SANN) — Cash Flow Reinvestment Rate

Latest as of December 2023: 0.00x

Santhera Pharmaceuticals Holding AG (SANN) has a Cash Flow Reinvestment Rate of 0.00x as of December 2023, reinvesting CHF90.00K (capex CHF90.00K ) from operating cash flow of CHF62.63 Million. Check cash flow quality index of Santhera Pharmaceuticals Holding AG to evaluate the quality of earnings relative to operating cash generation.

Reinvestment Rate

0.00x

(Capex + Investments) / Operating CF

Total Reinvested

CHF90.00K

Capex + Investments

Operating Cash Flow

CHF62.63 Million

CHF

Capital Expenditures

CHF90.00K

CHF

Santhera Pharmaceuticals Holding AG Cash Flow Reinvestment Rate (2019–2023)

Historical reinvestment intensity for Santhera Pharmaceuticals Holding AG across 2 annual periods. Explore Santhera Pharmaceuticals Holding AG strategic investment ratio to see how much of total assets are deployed in long-term investments.

Annual Cash Flow Reinvestment Rate for Santhera Pharmaceuticals Holding AG (2019–2023)

Year-by-year capital reinvestment analysis for Santhera Pharmaceuticals Holding AG. For live market cap and broader valuation context, see SANN stock market capitalisation.

Year	Reinvestment Rate	Total Reinvested (CHF)	Operating CF	Capex	YoY Change
2023	0.88x	CHF41.79 Million	CHF47.27 Million	CHF23.74 Million	▲ +828.7%
2019	0.10x	CHF247.00K	CHF2.60 Million	CHF229.00K	—

Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow